The pandemic has highlighted the importance of curbing the transmission of pathogens, which is expected to drive significant growth in the surface coating market. According to projections, the market value is set to soar to $3.5 billion by 2025, a substantial increase from its 2020 value of $1.3 billion.
FendX Technologies (Ticker: FNDX.c), a newly listed company, stands out in the industry by providing cutting-edge surface coating solutions utilizing its proprietary nanotechnology, making it a distinctive and promising player.
Dr. Carolyn Myers, CEO of FNDX, did a brief interview after opening the CSE on April 13th which sheds a lot of light on the company and its technology. Watch here:
Myers describes how FNDX has developed nanotechnology which has repelling properties that prevent the adhesion of viruses, bacteria, and any liquids (including blood). This nanotech is anticipated to significantly aid in the control of infectious diseases, especially in healthcare settings.
FNDX's first product is REPELWRAP™ film. This film can be applied to surfaces that are prone to contamination and uses FNDX's nanotech to repel pathogens thus preventing their transmission. REPELWRAP™ film is in the process of being transitioned from the lab to a manufacturer for scale-up, and it is expected to be introduced to the Canadian market in 2024.
During the interview, Myers says that the company is looking into creating other nanotech-powered products such as catheter coatings. Although FNDX's catheter coatings are in very early stages of production, FNDX's expectation is that they will be able to prevent blood clotting and bacterial biofilm formation within catheters.
She also details FNDX's highly experienced team and the specific roles that they perform, including the lead researchers who created the company's nanotechnology. The video is a great watch for anyone interested in FNDX or the surface coating market. Posted on behalf of FendX Technologies Inc.